Grzegorz S. Nowakowski, MD

Grzegorz S. Nowakowsi, MD, a consultant in the Division of Hematology in the Department of Internal Medicine and the Enterprise Deputy Director of Clinical Research at the Mayo Clinic Comprehensive Cancer Center

Articles

A Closer Look at the Potential Impact of Bispecific Antibodies on the DLBCL Treatment Landscape

July 18th 2022

Physicians speculate on the potential impact of bispecific antibodies on the treatment landscape of DLBCL.

Comparing Real-World Evidence With Data From Clinical Trials

July 18th 2022

The panelists discuss the importance of using real-world evidence in addition to data from clinical trials to inform decision-making.

Tafasitamab plus Lenalidomide as a Treatment in Patients With R/R DLBCL

July 7th 2022

Oncologists discuss the efficacy and safety of a tafasitamab plus lenalidomide for relapsed/refractory DLBCL and share personal experiences relevant to its use.

Selecting Among Available Treatment Options for Patients With Relapsed/Refractory DLBCL

July 7th 2022

Caron Jacobson, MD, and Matthew Lunning, DO, FACP, assess the available treatment options for patients with R/R DLBCL.

Improving Outcomes in Patients With DLBCL

June 30th 2022

Drs Locke and Gordon explain how outcomes for patients with DLBCL have improved as treatments continue to evolve.

A Focus on Frontline Treatment in Patients With DLBCL

June 30th 2022

Experts in lymphoma discuss how they risk stratify patients and the currently available options for first-line diffuse large-b cell lymphoma treatment.

Concluding Thoughts on the DLBCL Treatment Landscape

February 24th 2022

DLBCL experts share their thoughts on the changing treatment landscape and emerging treatments in large B-cell lymphomas.

Use of CAR T-Cell Therapies in Earlier Lines of DLBCL

February 24th 2022

Panelists discuss data on the use of CAR T-cell therapies in earlier lines and implications of these data on the DLBCL treatment landscape going forward.

Monoclonal Antibodies for Treatment of R/R DLBCL

February 17th 2022

Dr Nowakowski shares data from CD19-targeting monoclonal antibodies in treatment of R/R DLBCL.

Real-World Data With CAR-T Therapies in R/R DLBCL

February 17th 2022

Dr Westin discusses real-world data with CAR T-cell therapies in R/R DLBCL that were presented at ASH 2021.

Safety With CAR-T Therapies in R/R DLBCL

February 10th 2022

Dr Maziarz provides an overview of adverse events with CAR T-cell therapies and approaches to managing toxicities.

CAR-T Therapies in R/R DLBCL

February 10th 2022

Panelists discuss data with CAR T-cell therapies in treatment of relapsed and refractory DLBCL.

CAR-T Therapy

February 3rd 2022

Dr Miklos provides an overview of chimeric antigen receptor T (CAR-T) cell therapy.

Refractory vs Relapsed Patients with Diffuse Large B-Cell Lymphoma

February 3rd 2022

Dr Nowakowski discusses patient heterogeneity and treatment of relapsed vs refractory patients with DLBCL.

Relapsed and Refractory Diffuse Large B-Cell Lymphoma

January 24th 2022

A panel of diffuse large B-cell lymphoma experts discuss patient criteria and treatment selection in relapsed/refractory DLBCL.

Front-Line Treatment of DLBCL

January 24th 2022

Drs Westin, Miklos, and other panelists discuss the standard of care and emerging frontline treatments for diffuse large B-cell lymphoma.

Diffuse Large B-Cell Lymphoma Overview: An Aggressive Heterogenous Disease

December 23rd 2021

A panel of oncologists talks about diffuse large B-cell lymphoma, what patient and disease factors one should take into account when thinking about DLBCL.

Dr. Nowakowski on the Rationale of the ENGINE Trial in DLBCL

September 22nd 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for the ongoing, randomized phase 3 ENGINE study in diffuse large B-cell lymphoma.

Dr. Nowakowski on the Rationale for Reevaluating Enzastaurin in DLBCL

August 18th 2020

Grzegorz S. Nowakowski, MD, discusses the rationale for reevaluating the PCKß inhibitor enzastaurin in diffuse large B-cell lymphoma.

Dr. Nowakowski on Potential Clinical Implications of the ENGINE Study in DLBCL

August 12th 2020

Grzegorz S. Nowakowski, MD, discusses the potential clinical implications of the ongoing, randomized phase 3 ENGINE study in patients with high-risk Denovo Genomic Marker 1–positive diffuse large B-cell lymphoma.